Back to discover
Disease

Headache

Late-stage therapeutic developmentEmerging researchCooling momentum
10
Publications
24
Clinical trials
5
Related conditions
2025
Latest publication
Latest activity
beta

Recent clinical, regulatory, research and industry developments relating to this disease.

Symptoms, complications and management of long COVID: a review.

Research2021-07-15Journal of the Royal Society of Medicine

Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine.

Research2020-12-10The New England journal of medicine

Mechanisms of migraine as a chronic evolutive condition.

Research2019-12-23The journal of headache and pain

Idiopathic intracranial hypertension: consensus guidelines on management.

Research2018-06-14Journal of neurology, neurosurgery, and psychiatry

What's happening now

An analyst briefing on current research, clinical, regulatory and industry activity surrounding this disease.

Major developments
Clinical Milestones10View all 10
+2 more in the activity timeline below
Activity timeline10

Therapeutic landscape

Therapies with a regulatory footing for this condition, alongside the wider set of agents co-studied with it in the literature.

Approved & established therapies

Approval — RAYVOW is indicated for the acute treatment of the headache phase of migraine attacks, wi… (2022)

Clinical trials

17 sponsors · 2 new · 1 completed in the last 12 months (net +2)

The current development programme across all trial phases.

Clinical programme
24
All trials
6
Active
18
Late-stage
6
Completed
Late-stage studies
Recruiting
Recently completed

Regulatory timeline

Drug regulatory events matched to this condition by indication — EMA.

First approvals
2022emaApprovalLasmiditan Succinate· RAYVOW is indicated for the acute treatment of the headache phase of migraine attacks, with or without aura in adults. source ↗

European Medicines Agency (CC BY 4.0). Events are matched to this condition by drug indication text — approvals/updates for drugs indicated for it, not disease-specific acts.

Research activity

10 papers

Key research shaping understanding of this disease, combining the latest publications with the most influential evidence.

Publications over time
20182025
Most influential

Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine.

The New England journal of medicine · 2020 · 12,089 cites

Symptoms, complications and management of long COVID: a review.

Journal of the Royal Society of Medicine · 2021 · 611 cites

Idiopathic intracranial hypertension: consensus guidelines on management.

Journal of neurology, neurosurgery, and psychiatry · 2018 · 391 cites

Mechanisms of migraine as a chronic evolutive condition.

The journal of headache and pain · 2019 · 175 cites
Recent publications
Major themes8
  • Mental Disorders2
  • Pseudotumor Cerebri2
  • Adverse Drug Reaction Reporting Systems1
  • Banisteriopsis1
  • Epilepsy1
  • Glucagon-Like Peptide-1 Receptor Agonists1
  • Hallucinogens1
  • Headache1
Leading journals6
  • The journal of headache and pain4
  • European psychiatry : the journal of the Association of European Psychiatrists1
  • Journal of neurology, neurosurgery, and psychiatry1
  • Journal of psychopharmacology (Oxford, England)1
  • Journal of the Royal Society of Medicine1
  • Scientific reports1
Leading researchers8
  • Absalon J1
  • Aiyegbusi OL1
  • Andreou AP1
  • Bailey R1
  • Breeksema JJ1
  • Bsteh G1
  • Burdon MA1
  • Burstein R1
Affiliations (unnormalised)6
  • Danish Headache Center2
  • Alder Hey Children's NHS Foundation Trust1
  • Amsterdam University Medical Center1
  • Australian Institute of Migraine1
  • Birmingham Health Partners Centre for Regulatory Science and Innovation1
  • Center for Infectious Medicine1

Related conditions

5 matches

Diseases frequently studied alongside this one. Number shows shared papers.

Disease profile

A grounded synthesis of the condition — overview, causes, mechanism, risk factors and current standard of care.

Overview

Headache is pain in the cranial region. It may occur as an isolated benign symptom or as a manifestation of a wide variety of headache disorders.

Causes

Headache has a broad etiology and may arise as a symptom of many different headache disorders. The supplied grounding does not support a more specific causal classification beyond this general statement.

Pathophysiology

The supplied grounding does not provide a specific biological mechanism for headache itself. It only indicates that headache can be a symptom within diverse headache disorders, including conditions such as migraine and idiopathic intracranial hypertension.

Risk factors

The supplied grounding does not identify specific risk factors for headache in general. It does note that headache can occur in the context of long COVID and other headache disorders, but does not support broader risk-factor statements.

Current standard of care

Management is described only at a general level in the supplied grounding. Headache disorders are treated with a range of therapies, and the literature on idiopathic intracranial hypertension emphasizes interdisciplinary management; long COVID reviews also note multidisciplinary care for persistent symptoms. No specific drug classes or treatment regimens for headache itself are supported by the grounding.

AI-generated summary grounded in MeSH and 6 peer-reviewed sources. Informational only — not medical advice. Generated 2026-07-07.

Reference

Authoritative identity, definition & identifiers.

Defined in MeSH

The symptom of PAIN in the cranial region. It may be an isolated benign occurrence or manifestation of a wide variety of HEADACHE DISORDERS.

Identifiers
References & data sources
  • Disease identity & definition — NLM Medical Subject Headings (MeSH), public domain
  • Clinical trials — ClinicalTrials.gov (U.S. National Library of Medicine)
  • Research activity — Europe PMC (EMBL-EBI) + OpenAlex-derived paper links
  • Related entities are derived from literature co-mention (studied together) — associative, not causal.